Predictor of Anemia Among People Living With Hiv Taking Tenofovir+lamivudine+efavirenz Therapy in Jayapura, Papua

Abstract

Background: The most common hematological abnormality among people infected with Human Immunodeficiency Virus (HIV) is anemia. This is also related to high mortality risk among patients receiving Antiretroviral Therapy (ART). Purpose: This study aimed to identify predictorsf anemia among HIV patients taking ART using a regimen of the single-tablet drug contain tenofovir, lamivudine, and efavirenz in Jayapura, Papua. Methods: This was a cross-sectional study conducted at Jayapura regional hospital from June to September 2017. A total of 80 HIV patients were eligible for analysis. Data collection was conducted through an interview, medical record, measurement, and laboratory assay. The significance of differences among categorical variables was analyzed using Fisher’s exact test. The variables with p < 0.25 were then analyzed using binary logistic regression to determine predictors associated with anemia. A threshold of p < 0.05 indicates statistical significance. Results: This study showed that Body Mass Index (BMI) <18.50 (p = 0.01; OR = 5.63; 95% CI = 1.43 < OR < 22.19), length onRT ≤12 months (p = 0.00; OR = 4.90; 95% CI = 1.65 < OR < 14.53), and Cluster of Differentiation 4 (CD4+) percentage out of normal (p = 0.02; OR = 0.19; 95% CI = 0.05 < OR <0.77) had a significant association with anemia. Conclusion: BMI, length on ART, and CD4+ percentage were predictors of anemia among HIV patients taking antiretroviral therapy contain tenofovir, lamivudine, efavirenz regimen in Jayapura.

Adherence Determinant Analysis of Plhiv on Arv (Antiretroviral) Therapy in Situbondo District

“…As of March 2022, the number of newly-diagnosed People Living with HIV/AIDS (PLHIV) who were still alive and aware of their HIV status was 393.538, with 41% of them already on ART (PLHIV currently undergoing antiretroviral therapy) (2). PLHIV require Antiretroviral (ARV) therapy to suppress the amount of HIV in the body (3).…”

Protective and Ameliorative Effects of Hydroethanolic Extract of Piper nigrum (L.) Stem against Antiretroviral Therapy-Induced Hepatotoxicity and Dyslipidemia in Wistar Rats

“…It was approved by the Food and Drug Administration in 2001 for the treatment of HIV and is now the backbone of many antiretroviral therapy combinations [20,21]. One of these combinations is the regimen TDF300 mg/lamivudine 300 mg/efavirenz 400 mg. As a combination, observed TLE side efects are headache, nausea, nightmares, drowsiness, vomiting, insomnia, loss of appetite, diarrhea, and allergies [22].…”